Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) — In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the approval of four new options. This includes the groundbreaking introduction of Lilly’s Omvoh (mirikizumab), the inaugural IL-23 inhibitor for UC,…Read More
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape
